2-(5-methyl-1H-imidazol-1-yl)acetic acid | 933682-19-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(5-methyl-1H-imidazol-1-yl)acetic acid
• 英文别名: 2-(5-methylimidazol-1-yl)acetic acid
• CAS: 933682-19-0
• 化学式: C₆H₈N₂O₂
• mdl: MFCD11052998
• 分子量: 140.14
• InChiKey: FQLFGQKWJNALEN-UHFFFAOYSA-N

物化性质

• 沸点：
  389.9±25.0 °C(Predicted)
• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20200085821A1

  公开（公告）日：2020-03-19

  Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, R a , R a ′, R b , R c , X 1 , X 2 , X 3 , R d , Z 1 , and Z 2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.

  本发明揭示了化学实体，其为式（I）的化合物或其药学上可接受的盐；其中Y、Ra、Ra′、Rb、Rc、X1、X2、X3、Rd、Z1和Z2具有所述的值，星号标记的立体化学构型表示绝对立体化学。根据本发明的化学实体可用作Sumo激活酶（SAE）的抑制剂。还提供了含有本发明化合物的制药组合物以及使用该组合物治疗增殖性、炎症性、心血管和神经退行性疾病或疾患的方法。
• 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators
  申请人：Samuel Rachel G.

  公开号：US20100286191A1

  公开（公告）日：2010-11-11

  The invention encompasses compounds of Formula I or pharmaceutically acceptable salts thereof, which are modulators of the CXCR3 chemokine receptor function useful for the treatment or prevention of pathogenic inflammatory processes, autoimmune diseases or graft rejection processes. Methods of use and pharmaceutical compositions are also encompassed.

  本发明涵盖公式I的化合物或其药学上可接受的盐，它们是CXCR3趋化因子受体功能调节剂，可用于治疗或预防病原体炎症过程、自身免疫性疾病或移植排斥过程。本发明还涵盖使用方法和制药组合物。
• Heteroaryl compounds useful as inhibitors of sumo activating enzyme
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US10335410B2

  公开（公告）日：2019-07-02

  Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra′, Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.

  所公开的化学实体为式（I）化合物： 或其药学上可接受的盐；其中 Y、Ra、Ra′、Rb、Rc、X1、X2、X3、Rd、Z1 和 Z2 具有本文所述的值，星号位置描述的立体化学构型表示绝对立体化学。根据本公开的化学实体可用作苏木活化酶（SAE）的抑制剂。进一步提供了包含本公开化合物的药物组合物，以及使用该组合物治疗增殖性、炎症性、心血管和神经退行性疾病或紊乱的方法。
• Heteroaryl compounds useful as inhibitors of SUMO activating enzyme
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US10780090B2

  公开（公告）日：2020-09-22

  Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra′, Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.

  所公开的化学实体为式（I）化合物： 或其药学上可接受的盐；其中 Y、Ra、Ra′、Rb、Rc、X1、X2、X3、Rd、Z1 和 Z2 具有本文所述的值，星号位置描述的立体化学构型表示绝对立体化学。根据本公开的化学实体可用作苏木活化酶（SAE）的抑制剂。进一步提供了包含本公开化合物的药物组合物，以及使用该组合物治疗增殖性、炎症性、心血管和神经退行性疾病或紊乱的方法。
• US9683003B2
  申请人：——

  公开号：US9683003B2

  公开（公告）日：2017-06-20